Rivaroxaban Once Daily Versus Dose-adjusted Vitamin K Antagonist on the Biomarkers in Acute Decompensated Heart Failure and Atrial Fibrillation (ROAD HF-AF)

Last updated: January 9, 2019
Sponsor: Yonsei University
Overall Status: Active - Recruiting

Phase

4

Condition

Heart Failure

Chest Pain

Congestive Heart Failure

Treatment

N/A

Clinical Study ID

NCT03490994
4-2017-0776
  • Ages > 19
  • All Genders

Study Summary

Vitamin K antagonists (VKAs) are used to reduce the risk of stroke (cerebral vascular dysfunction) in AF patients. However, VKAs interact with drugs/food and the drug level is influenced by worsening of renal function, liver congestion or hemodynamic alterations in acute decompensated heart failure (ADHF). New oral anticoagulants (rivaroxaban, apixaban, dabigatran) are alternatives to VKA, such as warfarin. In post hoc analysis of ROCKET AF trial, 63.7% patients had HF and treatment-related outcomes were similar in patients with and without HF (Circulation HF. 2013; 6:740-7). So rivaroxaban 20 mg daily (or 15 mg daily in patients with creatinine clearance 30-49 mL/min) was safe in nonvalvular AF patients with HF. However, the clinical effect and safety of rivaroxaban were largely unknown in acute decompensated heart failure (ADHF) patients with atrial fibrillation (AF).

ROAD HF-AF is the exploratory study to assess the change of surrogate markers (hsTn, d-dimer) when treated with rivaroxaban vs. warfarin and to strengthen the basis for future biomarker-based therapy in ADHF patients

Eligibility Criteria

Inclusion

Inclusion Criteria:Hospitalized patients with a primary diagnosis of ADHF with AF One ofthe following criteria and LVEF ≤ 40% (at least 1 year before admission or admission)

  1. dyspnea at rest

  2. tachypnea; a respiratory rate > 20/min

  3. rales

  4. pulmonary edema on chest X-ray

Exclusion

Exclusion Criteria:

  1. History of increased bleeding risk (like ROCKET AF exclusion criteria)

  2. Contraindication to anti-coagulation therapy

  3. ACS diagnosis

  4. Hospitalization plan for PCI, coronary artery bypass graft surgery, other cardiacinvasive interventions (e.g. catheter ablation, pacemaker, CRT, ICD implantation)

  5. Currently on dual anti-platelet therapy (aspirin + ADP receptor antagonist) or singleantiplatelet therapy with a novel AP (e.g. Ticagrelor, Prasugrel)

  6. Cardiogenic shock (systolic blood pressure, SBP, < 80 mmHg)

  7. Patients with CrCl < 30 ml/min using creatinine-based CKD-EPI equations

  8. Elevated liver enzymes (3 times over upper reference limit) or liver cirrhosis

  9. Uncontrolled hypertension (SBP > 180 mmHg)

  10. Allergy, adverse drug reaction, hypersensitivity to rivaroxaban or warfarin

  11. Life expectancy < 6 months (e.g. metastatic malignancy)

  12. Pregnancy, or women of childbearing age

Study Design

Total Participants: 150
Study Start date:
April 10, 2018
Estimated Completion Date:
January 31, 2020

Connect with a study center

  • Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine

    Seoul, 120-752
    Korea, Republic of

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.